BACKGROUND - The standard therapy for R/M HNSCC includes anti-PD1. The combination A + B could be synergistic according to encouraging antitumor activity and safety in various tumor types and approval for hepatocellular carcinoma.

METHODS - This mCore network investigator-initiated, multi-center, single arm, phase 2 trial evaluated the combination of A (1200 mg) + B (15 mg/kg), given intravenously every 3 weeks, after progression on platinum-based chemotherapy in R/M HNSCC pts naïve for anti-PD1. The primary endpoint was objective response rate as per RECIST V1.1 after 18 weeks of treatment (ORR18w). The trial used an adaptive Simon 2-stage design. In the HPV negative cohort, we hypothesized that excluding an ORR18w ≤5% (null hypothesis) while targeting an ORR18w ≥30% (relevant hypothesis, power 80%) or ≥35% (high power, hypothesis 90%) would be an optimal approach.

At the end of the stage I, if less than 5 objective response were reported in the first 27 evaluable patients, the study will be closed for futility. Secondary endpoints included: disease control rate as per RECIST V1.1 after 18 weeks (DCR18w), progression free survival (PFS), overall survival (OS) and adverse events (AE).

RESULTS - A total of 30 pts (24 males, median age: 64.0 years [range:39-77.0]) were enrolled in the HPV negative cohort. Among the 28 pts evaluable for the primary endpoint, the ORR18w was 3.6% (1.28, unilateral 95% lower confidence limit: 0.2%). The DCR18w was 17.9% (95%CI: 6.1-36.9). With a median follow-up of 75.1 weeks (range: 2.9-100.9), the median PFS and OS were 6.2 (95%CI: 5.7 - 12.7) and 41.1 weeks (95%CI: 28.4 - 80.4), respectively.

Main AE (≥10%, all grades) related to A were thyroid disorders, diarrhea, fatigue, transaminase increase, arthralgia and pruritus. Main AE (≥10%, all grades) related to B were fatigue, proteinuria and hypertension. Eleven pts (36.7 %) experienced at least one Grade 3 related AE and 13.3% at least one SAE related to study drugs including one sudden death.

CONCLUSION - Based on the first stage of this study, the efficacy of A+B is limited in HPV negative-RM-HNSCC and does not warrant further investigation.

STUDY OVERVIEW

This multicenter, open-label, phase II proof-of-concept study was conducted according to an adaptive Simon two-stage design.

Key inclusion criteria:
- Adult patients with recurrent or metastatic HNSCC
- Histology of head and neck squamous cell carcinoma
- No prior PD1/PD-L1 i.v. or nivolumab therapy
- No prior tyrosine kinase inhibitors
- Two or more lines of prior therapy
- Measurable disease by per RECIST V1.1

Primary endpoint:
- RECIST V1.1
- Objective response rate (ORR)
- Disease control rate (DCR)
- Progression-free survival (PFS)
- Overall survival (OS)
- Serious adverse events (SAE)

Secondary endpoints:
- Atezolizumab and bevacizumab cohort
- ORR18w as per RECIST V1.1
- DCR18w
- Clinical benefit rate
- PFS
- OS
- SAE

Among the 30 patients enrolled and treated, median number of cycle for atezolizumab and bevacizumab was 3 [1-24]. At time of the analysis, all patients had discontinued both study treatments, mainly for progression.

Among the 28 patients evaluable at the end of Stage I, the ORR18w was 3.6% (1 patient with PR). According to the Simon 2-stage design, the HPV negative cohort was closed for futility.

10 patients had SD and 3 patients reached PR as best response.

EFFICACY ENDPOINTS

Among the 10 patients (33.3%) with at least one SAE, 7 patients had at least one SAE related to the study drugs according to the Sponsor (Grade 4 general health deterioration, Grade 4 hyponatremia with a Grade 3 tumor haemorrhage, Grade 3 colitis and a fatal case of tumor haemorrhage with pharyngeal fistula, one case of sudden death, a Grade 3 pneumonia, a Grade 3 sepsis).

The fatal tumor haemorrhage was a toxic effect reported in a 65-year male with pharyngeal fistula related to study treatment. The sudden death was related to cardiovascular origin, favored by smoking history and cervical irradiation. It was possibly related to study drugs for the Sponsor and reported as a SUSB.

CONCLUSION

Based on the first stage of this study, the efficacy of atezolizumab + bevacizumab is limited in HPV negative-RM-HNSCC and does not warrant further investigation. Median OS was similar to OS reported for other immunotherapies after failure of platinum-based treatment.

HPV positive cohort (N=3) was closed for enrolment in March 2022 due to very low accrual.

Translational research on pre and on-treatment tumor biopsies, blood samples and stool samples is ongoing.

Acknowledgments: We would like to thank the patients and their families, all the study staff from participating centers. The Study was supported by F Hoffmann-La Roche. First author has no conflict of interest.  


1: Centre Léon Bérard, Medical Oncology Department, Lyon, France; 2: Centre Antoine Lacassagne, Medical Oncology Department, Nice, France; 3: Centre Léon Bérard; 4: Clinical research platform (DCR), Lyon, France; 5: Centre Paul Strasbourg, Institut de Cancérologie Strasbourg Est (ICANS), Strasbourg, France; 6: Odonec Toulouse, Medical Oncology Department, Toulouse, France; 5: Clinique Vivaldel, Rennes, France; 6: Centre René Bucari, Rennes, France.

Abstract ID 676P - ATHENA - A multicenter Phase II trial of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC): the HPV negative cohort.

From May 2019 to November 2021, 30 R/M HNSCC patients were enrolled and treated with at least one dose of both study drugs (80% men, median age: 64 years [39-77], PS ECOG: 1.66%). At inclusion, all patients, except 1, had stage IV HNSCC. Median delay between the last progression/relapse to inclusion was 1.1 month [0.1-1.6]. Main metastatic site was lung (63.3%). All patients were enrolled after 1 or 2 line of prior treatment in the advanced/metastatic setting including a platinum-based therapy except 1 ineligibility criteria.

Primary tumor site
- Hypopharynx: 5 (16.7%)
- Larynx: 2 (6.7%)
- Oral cavity: 11 (36.7%)
- Oropharynx: 12 (40.0%)

Histological type
- Well differentiated squamous carcinoma: 15 (50.0%)
- Moderately differentiated squamous carcinoma: 8 (26.7%)
- Poorly differentiated squamous carcinoma: 7 (23.3%)

AJCC stage at initial diagnosis*
- T1: 7 (23.3%)
- T3: 1 (3.3%)
- TIV: 26 (86.7%)

Metastases at initial diagnosis*
- M0: 26 (86.7%)
- M1: 3 (10.0%)

N metastatic sites at inclusion
- 0: 33 (106.7%)
- 1: 2 (6.7%)
- 2: 17 (56.7%)
- 3: 5 (16.6%)

N prior lines before inclusion**
- 1: 27 (90.0%)
- 2: 1 (3.3%)
- 3: 1 (3.3%)

* Missing data n=1; ** T patient enrolled with no prior systemic line in metastatic setting.

Table 1: Characteristics of the atezolizumab and bevacizumab cohort.